Institute of Life Science 2 Internal Atrium

Dr Marcos Quintela Vazquez

Affiliate

Other/Subsidiary Companies - Not Defined

m.quintelavazquez@swansea.ac.uk

Available For Postgraduate Supervision

Research Links

ResearchGate

About

Based at the Medical School, Dr Quintela is a Research and Development Innovation Officer in the Reproductive Biology and Gynaecological Oncology (RBGO) research group. Dr Quintela graduated from his bachelor’s degree at the University of Salamanca (Spain) in 2012. He then undertook his master’s degree in Biotechnology at the Autonomous University of Barcelona (Spain) and in 2014 he moved to the UK to start a PhD in Nanomedicine at Swansea University. His PhD was undertaken in partnership with the Houston Methodist Research Institute, where he spent two years working as a Graduate Research Fellow. After completing his PhD, Marcos joined the College of Medicine as a researcher, first working within Data Science and now as part of the RBGO group.

Areas Of Expertise

Cell and molecular biology
Genomics and epigenomics
Bioinformatics, omics data analysis
Reproductive biology and gynaecological oncology
Drug development

Career Highlights

Teaching Interests

Marcos lectures for the Nanomedicine MSc course in a wide range of modules.

Research Collaborations

Publications

Research Highlights

Friguglietti, J., Das, S., Le, P., Fraga, D., Quintela Vazquez, M., Gazze, S., McPhail, D., Gu, J., Sabek, O., Gaber, A., Francis, L., Zagozdzon-Wosik, W., & Merchant, F. (2020). Novel Silicon Titanium Diboride Micropatterned Substrates for Cellular Patterning. Biomaterials, 244, 119927
https://doi.org/10.1016/j.biomaterials.2020.119927, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa54548
Rees, P., Bauza‐Mayol, G., Quintela Vazquez, M., Brozovich, A., Hopson, M., Shaikh, S., Cabrera, F., Shi, A., Niclot, F., Paradiso, F., Thomson, E., Jovic, T., Rees, P., Tasciotti, E., Francis, L., Mcculloch, P., & Taraballi, F. (2021). Biomimetic Scaffolds Modulate the Posttraumatic Inflammatory Response in Articular Cartilage Contributing to Enhanced Neoformation of Cartilaginous Tissue In Vivo. Advanced Healthcare Materials, 11(1), 2101127
https://doi.org/10.1002/adhm.202101127, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa58476
PARADISO, F., Quintela Vazquez, M., Lenna, S., Serpelloni, S., James, D., Caserta, S., Conlan, S., Francis, L., & Taraballi, F. (2022). Studying Activated Fibroblast Phenotypes and Fibrosis‐Linked Mechanosensing Using 3D Biomimetic Models. Macromolecular Bioscience, 22(4), 2100450
https://doi.org/10.1002/mabi.202100450, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa59159
TOUBHANS, B., Alkafri, N., Quintela Vazquez, M., James, D., Bissardon, C., Gazze, S., Knodel, F., Proux, O., Gourlan, A., Rathert, P., Bohic, S., Gonzalez, D., Francis, L., Charlet, L., & Conlan, S. (2023). Selenium nanoparticles modulate histone methylation via lysine methyltransferase activity and S-adenosylhomocysteine depletion. Redox Biology, 61, 102641
https://doi.org/10.1016/j.redox.2023.102641, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa62755
Quintela Vazquez, M., James, D., Baseviciene, A., Powell, L., Edwards, K., Coombes, Z., Garcia, J., Garton, N., Das, N., Lutchman-Singh, K., Margarit, L., Beynon, A., Rioja, I., Prinjha, R., Harker, N., Gonzalez, D., Conlan, S., Francis, L., & Johnson, A. (2023). Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells. Clinical Epigenetics, 15(1)
https://doi.org/10.1186/s13148-023-01477-x, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa64098
James, D., Quintela Vazquez, M., Lucini, L., Al Kafri, N., Healey, G., Jones, N., Younas, K., Bunkheila, A., Margarit, L., Francis, L., Gonzalez, D., & Conlan, S. (2024). Homeobox regulator Wilms Tumour 1 is displaced by androgen receptor at cis-regulatory elements in the endometrium of PCOS patients. Frontiers in Endocrinology, 15
https://doi.org/10.3389/fendo.2024.1368494, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa66500

All Research

Journal Articles

James, D., Quintela Vazquez, M., Lucini, L., Al Kafri, N., Healey, G., Jones, N., Younas, K., Bunkheila, A., Margarit, L., Francis, L., Gonzalez, D., & Conlan, S. (2024). Homeobox regulator Wilms Tumour 1 is displaced by androgen receptor at cis-regulatory elements in the endometrium of PCOS patients. Frontiers in Endocrinology, 15
https://doi.org/10.3389/fendo.2024.1368494, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa66500
TOUBHANS, B., Alkafri, N., Quintela Vazquez, M., James, D., Bissardon, C., Gazze, S., Knodel, F., Proux, O., Gourlan, A., Rathert, P., Bohic, S., Gonzalez, D., Francis, L., Charlet, L., & Conlan, S. (2023). Selenium nanoparticles modulate histone methylation via lysine methyltransferase activity and S-adenosylhomocysteine depletion. Redox Biology, 61, 102641
https://doi.org/10.1016/j.redox.2023.102641, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa62755
Quintela Vazquez, M., James, D., Baseviciene, A., Powell, L., Edwards, K., Coombes, Z., Garcia, J., Garton, N., Das, N., Lutchman-Singh, K., Margarit, L., Beynon, A., Rioja, I., Prinjha, R., Harker, N., Gonzalez, D., Conlan, S., Francis, L., & Johnson, A. (2023). Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells. Clinical Epigenetics, 15(1)
https://doi.org/10.1186/s13148-023-01477-x, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa64098
PARADISO, F., Quintela Vazquez, M., Lenna, S., Serpelloni, S., James, D., Caserta, S., Conlan, S., Francis, L., & Taraballi, F. (2022). Studying Activated Fibroblast Phenotypes and Fibrosis‐Linked Mechanosensing Using 3D Biomimetic Models. Macromolecular Bioscience, 22(4), 2100450
https://doi.org/10.1002/mabi.202100450, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa59159
Rees, P., Bauza‐Mayol, G., Quintela Vazquez, M., Brozovich, A., Hopson, M., Shaikh, S., Cabrera, F., Shi, A., Niclot, F., Paradiso, F., Thomson, E., Jovic, T., Rees, P., Tasciotti, E., Francis, L., Mcculloch, P., & Taraballi, F. (2021). Biomimetic Scaffolds Modulate the Posttraumatic Inflammatory Response in Articular Cartilage Contributing to Enhanced Neoformation of Cartilaginous Tissue In Vivo. Advanced Healthcare Materials, 11(1), 2101127
https://doi.org/10.1002/adhm.202101127, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa58476
Friguglietti, J., Das, S., Le, P., Fraga, D., Quintela Vazquez, M., Gazze, S., McPhail, D., Gu, J., Sabek, O., Gaber, A., Francis, L., Zagozdzon-Wosik, W., & Merchant, F. (2020). Novel Silicon Titanium Diboride Micropatterned Substrates for Cellular Patterning. Biomaterials, 244, 119927
https://doi.org/10.1016/j.biomaterials.2020.119927, SU Repository: https://cronfa.swan.ac.uk/Record/cronfa54548

Taught Modules

PMLM01 Laboratory Measurement Techniques for Medicinal Chemistry and Nanomedicine

This module will enable students to understand the basic and advanced concepts of measurement techniques used in medicinal chemistry and nanomedicine, how they may be applied with relevant methods of detection, gain `hands on¿ problem solving experience and strategic method development for complete bioanalysis according to target molecule characteristics and method application.
PMNM11 Nanomedicines, pharmaceuticals and advanced therapeutics

This module will explore the history and development of molecular medicines and pharmaceuticals, providing the basis for an advanced understanding of next generation therapeutic approaches. Using landmark technology and chemical development phases informed by separation science and mass spectrometry, the module uses an application driven approach to provide the student with an extensive knowledgebase of drug development, the pharmaceutical industry and nanotherapeutics. Students will be able to characterize and map the path of a drug from administration, to metabolism and elimination, and critically evaluate drug design and delivery approaches. Traditional small chemical entities used in molecular medicine will be outlined, using drugs such as taxols and tamoxifen as exemplars. Common target oncology and non-oncology disorders will provide the context; with students encouraged to explore targeted nanoparticle fabrication, drug encapsulation and release profiling, from early first generation drugs such as Abraxane to second generation biologically targeted SMART delivery systems. Future molecular medicines such as antibody drug conjugates and kinase inhibitors will be taught by guest lectures from industry and clinicians, covering the spectrum of drug development to delivery and clinical considerations.